A. Ting

The Use of GMP-Produced Bone Marrow Derived Stem Cells in Combination with Extra Corporeal Membrane Oxygenation in ARDS -An Animal Model.

C. Bermudez, M. Rojas, N. Cárdenes, 2017, ASAIO journal.

Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial

R. Wunderink, D. Brealey, D. Thickett, 2021, Intensive Care Medicine.

Risk factors for the development of obliterative bronchiolitis after lung transplantation.

G. Berry, I. Johnstone, H. Reichenspurner, 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

The Use of GMP-Produced Bone Marrow-Derived Stem Cells in Combination with Extracorporeal Membrane Oxygenation in ARDS: An Animal Model.

C. Bermudez, M. Rojas, E. Koçyildirim, 2017, ASAIO journal.

Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

R. Wunderink, D. Brealey, D. Thickett, 2019, B14. LATE BREAKING CLINICAL TRIALS.

Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model

B. Lopresti, J. Carney, M. Rojas, 2019, BMJ Open Respiratory Research.